Even before the responsibilities of the new parliamentarians are invited by the Association of large Swiss pharmaceutical companies, interpharma you next Monday to lobby event. Many of you have to say, as René Buchholzer, Interpharma, the managing Director, this newspaper says. What will he say to the new national councils: New Biotech drugs to be approved faster in Switzerland and be reimbursed. And your price should be flexible. Because it is to be expected with a wave of breakthrough therapies for cancer and other serious diseases, in which prices of several hundred thousand Swiss francs are expected to remain no longer the exception.
"The dynamics of massive, data and medical Knowledge multiply the success of the Research", explains Jörg-Michael Rupp. He is a pharmaceutical-in-chief of Roche and currently the President inter Pharma. For patients this means: The number of diagnostic possibilities and thus the medical treatment options will grow exponentially. However, the rapid treatment can be inhibited by the length of time for approval. Another obstacle was the high prices that the insurance companies have reached your Limit.
to speak as quickly as Possible to patients
"We price question quite frankly, because we are aware of the responsibility towards the patients, the society, but also to the shareholders of the company aware," stresses Rupp. In the previous Swiss pricing model sets the price with a view of the foreign as well as comparable medications the feast, he sees a Problem. It is no longer fit for novel therapies.
The new funds are usually studied only after the approval in their effect over a longer period of time.
The Biotech therapies bring additional challenges: you should be able to quickly on the market, because you save may's life. The data from the clinical studies is usually sparse, because for the specialized therapies there are many exclusion criteria and therefore, only a few subjects. The effectiveness in the real-world application of the therapy in more patients, an application could, therefore, be different so Interpharma. The new resources are investigated usually only after the approval in their effect over a longer period of time.
inter-Pharma therefore relies on flexible prices: A therapy to be paid for after effect. This is low, it will cost you less. Pay for Performance means this model is already applied in some countries. Also, it should play a role, how many patients are treated with a new drug: The more these are, the lower the price for the individual patient could be.
"It must be a matter of whether or not a Patient after a certain period of time has a better health and quality of life."Santésuisse-speaker
health insurance associations Santésuisse as well as Curafutura are open for discussion. Also, they are not averse to a Pay-for-Performance model. However, Santésuisse makes it clear that in the case of the measurement of the effectiveness of the entire patient should be considered. "It must be a matter of whether or not a Patient after a certain period of time has a better health and quality of life," said the spokesperson.
Created: 06.12.2019, 20:07 PM